Article | August 1, 2022

The Patient-Centric Clinical Supply Chain For Cell And Gene Therapies

Source: Yourway, The Biopharma Services Company

By Fiona Geiger, Vice President of Client Services, Yourway


Cell and gene therapies present a new frontier in targeted, patient-centric treatments for a wide range of rare diseases that have not been well addressed by more conventional therapies. However, owing to the unique supply chains — particularly for autologous cell therapies — strict temperature controls and short viability windows of these products, delivering these therapies to patients requires new levels of agility, flexibility and innovation in the logistical management of supply. 

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Bioprocess Online

Yourway, The Biopharma Services Company